|
US20040028686A1
(en)
*
|
2001-06-28 |
2004-02-12 |
Faulk Ward Page |
Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplated organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
|
|
US7589180B2
(en)
|
2001-05-11 |
2009-09-15 |
Abbott Laboratories Inc. |
Specific binding proteins and uses thereof
|
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
US7087600B2
(en)
|
2001-05-31 |
2006-08-08 |
Medarex, Inc. |
Peptidyl prodrugs and linkers and stabilizers useful therefor
|
|
EP1610763A2
(de)
*
|
2003-03-31 |
2006-01-04 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Stabile liposome oder micellen mit einem sphingolipid und einem peg-lipopolymer
|
|
US7374762B2
(en)
|
2003-05-14 |
2008-05-20 |
Immunogen, Inc. |
Drug conjugate composition
|
|
WO2005042002A2
(en)
*
|
2003-10-30 |
2005-05-12 |
Entelos, Inc. |
Treatment of rhematoid arthritis with flip antagonists
|
|
US20070287680A1
(en)
*
|
2004-05-10 |
2007-12-13 |
University Of Utah Research Foundation |
Combined Active and Passive Targeting of Biologically Active Agents
|
|
US7517903B2
(en)
|
2004-05-19 |
2009-04-14 |
Medarex, Inc. |
Cytotoxic compounds and conjugates
|
|
US7691962B2
(en)
|
2004-05-19 |
2010-04-06 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
|
CN101102752A
(zh)
*
|
2004-11-15 |
2008-01-09 |
耶路撒冷希伯来大学伊萨姆研发公司 |
联合优选为神经酰胺与细胞毒性药物的联合疗法
|
|
JP5165387B2
(ja)
|
2005-02-11 |
2013-03-21 |
イムノゲン インコーポレーティッド |
安定な薬物複合体を調製するための方法
|
|
US20110166319A1
(en)
*
|
2005-02-11 |
2011-07-07 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
|
US7714016B2
(en)
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
|
WO2007019232A2
(en)
|
2005-08-03 |
2007-02-15 |
Immunogen, Inc. |
Immunoconjugate formulations
|
|
EP3539572A1
(de)
|
2005-08-24 |
2019-09-18 |
ImmunoGen, Inc. |
Verfahren zur herstellung von maytansinoid-antikörper-konjugaten
|
|
AU2006294554B2
(en)
*
|
2005-09-26 |
2013-03-21 |
E. R. Squibb & Sons, L.L.C. |
Antibody-drug conjugates and methods of use
|
|
CN101365679B
(zh)
|
2005-10-26 |
2012-11-14 |
梅达莱克斯公司 |
制备cc-1065类似物的方法和化合物
|
|
CA2627190A1
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
|
EP1806365A1
(de)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antikörper spezifisch für Fibroblasten-Aktivierungsprotein und Immunokonjugaten, die diese Antikörper enthalten
|
|
EA020324B1
(ru)
|
2006-07-18 |
2014-10-30 |
Санофи-Авентис |
АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
|
|
EP1914242A1
(de)
*
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Neue Antikörper gegen CD38 zur Behandlung von Krebs
|
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
梅達雷克斯有限責任公司 |
化學鏈接劑與可裂解基質以及其之綴合物
|
|
EP2126127B1
(de)
|
2007-01-25 |
2016-09-28 |
Dana-Farber Cancer Institute, Inc. |
Verwendung von anti-egfr-antikörpern bei der behandlung von durch egfr-mutanten vermittelten krankheiten
|
|
KR20090122439A
(ko)
|
2007-02-21 |
2009-11-30 |
메다렉스, 인코포레이티드 |
단일 아미노산을 갖는 화학적 링커 및 이의 접합체
|
|
CA2680854C
(en)
|
2007-03-15 |
2017-02-14 |
Ludwig Institute For Cancer Research |
Treatment method using egfr antibodies and src inhibitors and related formulations
|
|
PE20140196A1
(es)
|
2007-08-09 |
2014-03-19 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
|
US9283276B2
(en)
|
2007-08-14 |
2016-03-15 |
Ludwig Institute For Cancer Research Ltd. |
Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
|
|
EP3415529B1
(de)
|
2007-09-26 |
2020-11-04 |
Chugai Seiyaku Kabushiki Kaisha |
Modifizierte antikörperkonstantregion
|
|
US8742076B2
(en)
*
|
2008-02-01 |
2014-06-03 |
Genentech, Inc. |
Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
|
|
FR2933702A1
(fr)
*
|
2008-07-08 |
2010-01-15 |
Sanofi Aventis |
Antagonistes specifiques du recepteur fgf-r4
|
|
WO2010009124A2
(en)
|
2008-07-15 |
2010-01-21 |
Genentech, Inc. |
Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
|
|
JP6051048B2
(ja)
|
2009-03-25 |
2016-12-21 |
ジェネンテック， インコーポレイテッド |
新規な抗α５β１抗体及びその使用
|
|
EP2437790B1
(de)
|
2009-06-03 |
2019-02-20 |
Immunogen, Inc. |
Konjugationsverfahren
|
|
MX2012003396A
(es)
|
2009-09-16 |
2012-04-10 |
Genentech Inc |
Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos.
|
|
UY32914A
(es)
|
2009-10-02 |
2011-04-29 |
Sanofi Aventis |
Anticuerpos que se usan específicamente al receptor epha2
|
|
JP2013506709A
(ja)
|
2009-10-06 |
2013-02-28 |
イミュノジェン・インコーポレーテッド |
有効なコンジュゲートおよび親水性リンカー
|
|
EP2949670B1
(de)
|
2009-12-10 |
2019-02-27 |
F. Hoffmann-La Roche AG |
Vorzugsweise an die extrazelluläre domäne 4 von humanem csf1r bindende antikörper und deren verwendung
|
|
KR20130000384A
(ko)
|
2010-02-18 |
2013-01-02 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
뉴레귤린 길항제 및 암의 치료에서의 그의 용도
|
|
JP5989547B2
(ja)
|
2010-03-05 |
2016-09-07 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒトｃｓｆ−１ｒに対する抗体及びその使用
|
|
KR101656548B1
(ko)
|
2010-03-05 |
2016-09-09 |
에프. 호프만-라 로슈 아게 |
인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
|
|
BR112012022044A2
(pt)
|
2010-03-24 |
2020-08-25 |
Genentech Inc |
''anticorpo,imunoconjugado,formulação farmacêutica,uso do anticorpo,método de tratamento,anticorpo biespecifico isolado e célula hospedeira''.
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
CA2794731C
(en)
|
2010-06-18 |
2019-03-19 |
Genentech, Inc. |
Anti-axl antibodies and methods of use
|
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
|
BR112013002535A2
(pt)
|
2010-08-03 |
2019-09-24 |
F. Hoffmann - La Roche Ag |
biomarcadores de leucemia linfocítica crônica (cll)
|
|
KR101653030B1
(ko)
|
2010-08-13 |
2016-08-31 |
로슈 글리카트 아게 |
항-테나신-c a２ 항체 및 이의 사용 방법
|
|
CN104474546A
(zh)
|
2010-08-13 |
2015-04-01 |
弗·哈夫曼-拉罗切有限公司 |
用于疾病治疗的针对IL-1β和IL-18的抗体
|
|
SG187746A1
(en)
|
2010-08-13 |
2013-03-28 |
Roche Glycart Ag |
Anti-fap antibodies and methods of use
|
|
SG10201408229WA
(en)
|
2010-08-31 |
2015-02-27 |
Genentech Inc |
Biomarkers and methods of treatment
|
|
TW201300417A
(zh)
|
2010-11-10 |
2013-01-01 |
Genentech Inc |
用於神經疾病免疫療法之方法及組合物
|
|
ES2533710T3
(es)
|
2010-12-02 |
2015-04-14 |
Nerviano Medical Sciences S.R.L. |
Proceso para la preparación de derivados de morfolinil antraciclina
|
|
EP2652498B1
(de)
|
2010-12-16 |
2018-04-18 |
F.Hoffmann-La Roche Ag |
Diagnose und behandlungen im zusammenhang mit th2-hemmung
|
|
PE20170917A1
(es)
|
2010-12-20 |
2017-07-12 |
Genentech Inc |
Anticuerpos anti-mesotelina e inmunoconjugados
|
|
BR112013015687A2
(pt)
|
2010-12-22 |
2016-10-11 |
Genentech Inc |
anticorpo anti-pcsk9 ou um fragmento de anticorpo que se liga a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar um anticorpo anti-pcsk9, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito e método de tratamento de hipercolesterolemia em um sujeito
|
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
|
WO2012135517A2
(en)
|
2011-03-29 |
2012-10-04 |
Immunogen, Inc. |
Preparation of maytansinoid antibody conjugates by a one-step process
|
|
ES2692268T5
(en)
|
2011-03-29 |
2025-02-26 |
Roche Glycart Ag |
Antibody fc variants
|
|
TR201902180T4
(tr)
|
2011-03-29 |
2019-03-21 |
Immunogen Inc |
Tek adimli bi̇r i̇şlem i̇le maytansi̇noi̇d anti̇kor konjugatlarinin hazirlanmasi
|
|
BR112013024717A2
(pt)
|
2011-04-07 |
2017-08-08 |
Genentech Inc |
anticorpo isolado, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, método de tratar um indivíduo que tem câncer e método de inibir proliferação celular em um indivíduo
|
|
JP2014514313A
(ja)
|
2011-04-20 |
2014-06-19 |
ロシュ グリクアート アクチェンゲゼルシャフト |
血液脳関門のｐＨ依存性通過のための方法及び構築物
|
|
KR101623246B1
(ko)
|
2011-05-16 |
2016-05-20 |
제넨테크, 인크. |
Fgfr1 효능제 및 사용 방법
|
|
CA2837840C
(en)
|
2011-06-10 |
2020-08-04 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
WO2013003680A1
(en)
|
2011-06-30 |
2013-01-03 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
|
US20140363438A1
(en)
|
2011-08-17 |
2014-12-11 |
Genentech, Inc. |
Neuregulin antibodies and uses thereof
|
|
WO2013026835A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab fragments and methods of use
|
|
EP2747781B1
(de)
|
2011-08-23 |
2017-11-15 |
Roche Glycart AG |
Bispezifische antikörper spezifisch für t-zell-aktivierende antigene und ein tumorantigen sowie verwendungsverfahren
|
|
WO2013040433A1
(en)
|
2011-09-15 |
2013-03-21 |
Genentech, Inc. |
Methods of promoting differentiation
|
|
WO2013043715A1
(en)
|
2011-09-19 |
2013-03-28 |
Genentech, Inc. |
Combination treatments comprising c-met antagonists and b-raf antagonists
|
|
EP2758435A1
(de)
|
2011-09-23 |
2014-07-30 |
Roche Glycart AG |
Bispezifische anti-egfr-/anti-igf-1r-antikörper
|
|
CA2849011A1
(en)
|
2011-10-05 |
2013-04-11 |
Genentech, Inc. |
Methods of treating liver conditions using notch2 antagonists
|
|
CA2850514A1
(en)
|
2011-10-14 |
2013-04-18 |
Genentech, Inc. |
Peptide inhibitors of bace1
|
|
MX390891B
(es)
|
2011-10-14 |
2025-03-19 |
Genentech Inc |
ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO.
|
|
MX2014004426A
(es)
|
2011-10-15 |
2014-07-09 |
Genentech Inc |
Metodos de uso de antagonistas de scd1.
|
|
PH12014500925A1
(en)
|
2011-10-28 |
2014-06-09 |
Genentech Inc |
Therapeutic combinations and methods of treating melanoma
|
|
MX2014005885A
(es)
|
2011-11-21 |
2014-09-04 |
Genentech Inc |
Purificacion de anticuerpos anti-c-met.
|
|
EP2791174B1
(de)
|
2011-12-15 |
2018-02-28 |
F. Hoffmann-La Roche AG |
Antikörper gegen menschlichen csf-1r und deren verwendungen
|
|
CA2862424A1
(en)
|
2012-01-18 |
2013-07-25 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
|
US9200072B2
(en)
|
2012-01-18 |
2015-12-01 |
Genentech Inc. |
Anti-LRP5 antibodies and methods of use
|
|
CN104105711B
(zh)
|
2012-02-10 |
2018-11-30 |
弗·哈夫曼-拉罗切有限公司 |
单链抗体及其他异多聚体
|
|
HK1211037A1
(en)
|
2012-02-11 |
2016-05-13 |
霍夫曼-拉罗奇有限公司 |
R-spondin translocations and methods using the same
|
|
PL2814587T3
(pl)
|
2012-02-15 |
2018-10-31 |
F.Hoffmann-La Roche Ag |
Chromatografia powinowactwa oparta na receptorze Fc
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
WO2013160396A1
(en)
|
2012-04-26 |
2013-10-31 |
Boehringer Ingelheim International Gmbh |
Combination of cd37 antibodies with bendamustine
|
|
BR112014027166A2
(pt)
|
2012-05-01 |
2017-06-27 |
Genentech Inc |
anticorpo, ácido nucleico, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibir proliferação e métodos de detecção.
|
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
|
US8992915B2
(en)
|
2012-05-16 |
2015-03-31 |
Boehringer Ingelheim International Gmbh |
Combination of CD37 antibodies with ICE
|
|
JP2015517512A
(ja)
|
2012-05-16 |
2015-06-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｄ３７抗体の更なる薬剤との併用
|
|
SG11201407017WA
(en)
|
2012-06-04 |
2014-12-30 |
Irm Llc |
Site-specific labeling methods and molecules produced thereby
|
|
RU2015101113A
(ru)
|
2012-06-15 |
2016-08-10 |
Дженентек, Инк. |
Антитела против pcsk9, составы, дозы и способы применения
|
|
MX2014014804A
(es)
|
2012-06-27 |
2015-02-12 |
Hoffmann La Roche |
Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
|
|
EP2867253B1
(de)
|
2012-06-27 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Verfahren zur auswahl und herstellung massgeschneiderter, hochselektiver und multispezifischer targeting-einheiten mit mindestens zwei verschiedenen bindungseinheiten sowie verwendungen davon
|
|
EP2867255B1
(de)
|
2012-06-27 |
2017-07-19 |
F. Hoffmann-La Roche AG |
Verfahren zur auswahl und herstellung massgeschneiderter, selektiver und multispezifischer therapiemoleküle mit mindestens zwei verschiedenen targeting-einheiten sowie verwendungen davon
|
|
JP6324376B2
(ja)
|
2012-07-04 |
2018-05-16 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
抗テオフィリン抗体および使用方法
|
|
BR112014030844A2
(pt)
|
2012-07-04 |
2019-10-15 |
Hoffmann La Roche |
anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo
|
|
BR112014029403A2
(pt)
|
2012-07-04 |
2018-10-09 |
F. Hoffmann-La Roche Ag |
conjugados, anticorpo e formulação farmacêutica
|
|
CN104428007B
(zh)
|
2012-07-09 |
2018-03-16 |
基因泰克公司 |
包含抗cd22抗体的免疫缀合物
|
|
EP2869847B1
(de)
|
2012-07-09 |
2017-12-06 |
Genentech, Inc. |
Immunkonjugate mit anti-cd79b-antikörpern
|
|
LT3495387T
(lt)
|
2012-07-13 |
2021-11-25 |
Roche Glycart Ag |
Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
|
|
RU2661083C2
(ru)
|
2012-10-04 |
2018-07-11 |
Иммуноджен, Инк. |
Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
|
|
WO2014056783A1
(en)
|
2012-10-08 |
2014-04-17 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
|
WO2014072306A1
(en)
|
2012-11-08 |
2014-05-15 |
F. Hoffmann-La Roche Ag |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
|
JP6386465B2
(ja)
|
2012-11-13 |
2018-09-05 |
ジェネンテック， インコーポレイテッド |
抗ヘマグルチニン抗体及び使用方法
|
|
AU2012395148B2
(en)
|
2012-11-24 |
2016-10-27 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
CA2892863C
(en)
|
2012-12-10 |
2022-03-15 |
Mersana Therapeutics, Inc. |
Polymeric scaffold based on phf for targeted drug delivery
|
|
WO2014093379A1
(en)
|
2012-12-10 |
2014-06-19 |
Mersana Therapeutics, Inc. |
Auristatin compounds and conjugates thereof
|
|
EP2931316B1
(de)
|
2012-12-12 |
2019-02-20 |
Mersana Therapeutics, Inc. |
Hydroxylpolymer-heilmittelproteinkonjugate
|
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
|
CA2900755C
(en)
|
2013-02-08 |
2021-07-20 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
KR20150118159A
(ko)
|
2013-02-22 |
2015-10-21 |
에프. 호프만-라 로슈 아게 |
암의 치료 방법 및 약물 내성의 예방 방법
|
|
JP2016512489A
(ja)
|
2013-02-26 |
2016-04-28 |
ロシュ グリクアート アーゲー |
抗ｍｃｓｐ抗体
|
|
KR20150123250A
(ko)
|
2013-03-06 |
2015-11-03 |
제넨테크, 인크. |
암 약물 내성의 치료 및 예방 방법
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
EP3299391B1
(de)
|
2013-03-14 |
2019-12-04 |
Genentech, Inc. |
Anti-b7-h4-antikörper und immunkonjugate
|
|
KR20150127216A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
암의 치료 및 암 약물 내성의 예방 방법
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
WO2014144865A2
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Anti-crth2 antibodies and methods of use
|
|
BR112015021134A2
(pt)
|
2013-03-15 |
2017-10-10 |
Novartis Ag |
conjugados de fármaco e anticorpo
|
|
RU2015143437A
(ru)
|
2013-03-15 |
2017-04-27 |
Дженентек, Инк. |
Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака
|
|
WO2014151006A2
(en)
|
2013-03-15 |
2014-09-25 |
Genentech, Inc. |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
|
BR112015023262B8
(pt)
|
2013-03-15 |
2024-02-06 |
Ac Immune Sa |
Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
|
|
AU2014236815B2
(en)
|
2013-03-15 |
2019-04-04 |
Genentech, Inc. |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
|
EP2992010B1
(de)
|
2013-04-29 |
2021-03-24 |
F.Hoffmann-La Roche Ag |
Fc-receptorbindende asymmetrische modifizierte antikörper und verwendungsverfahren
|
|
EA038367B1
(ru)
|
2013-05-20 |
2021-08-16 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ РЕЦЕПТОРА ТРАНСФЕРРИНА (TfR) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
|
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
|
MX2016003248A
(es)
|
2013-09-17 |
2016-06-07 |
Genentech Inc |
Metodos de uso de anticuerpos anti-lgr5.
|
|
KR102572149B1
(ko)
|
2013-10-11 |
2023-08-30 |
아사나 바이오사이언시스 엘엘씨 |
단백질-폴리머-약물 접합체
|
|
KR102087850B1
(ko)
|
2013-10-11 |
2020-03-12 |
메르사나 테라퓨틱스, 인코포레이티드 |
단백질-고분자-약물 접합체
|
|
TW201940514A
(zh)
|
2013-10-18 |
2019-10-16 |
美商建南德克公司 |
抗-rspo抗體及使用方法
|
|
CA2931340A1
(en)
|
2013-12-13 |
2015-06-18 |
Genentech, Inc. |
Anti-cd33 antibodies and immunoconjugates
|
|
CA2928952A1
(en)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
Peptidomimetic compounds and antibody-drug conjugates thereof
|
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
|
EP3089758B1
(de)
|
2014-01-03 |
2021-01-27 |
F.Hoffmann-La Roche Ag |
Kovalent verknüpfte helikar-/anti-helikar-antikörperkonjugate und verwendungen davon
|
|
EP3089759B1
(de)
|
2014-01-03 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Kovalent verknüpfte polypeptidtoxin-antikörperkonjugate
|
|
ES2895752T3
(es)
|
2014-01-03 |
2022-02-22 |
Hoffmann La Roche |
Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
|
|
EP3105253B1
(de)
|
2014-02-12 |
2018-06-27 |
F. Hoffmann-La Roche AG |
Anti-jagged1-antikörper und verfahren zur verwendung
|
|
UA117608C2
(uk)
|
2014-02-21 |
2018-08-27 |
Дженентек, Інк. |
Спосіб лікування еозинофільного захворювання у пацієнта шляхом застосування біспецифічного анти-il-13/il-17 антитіла
|
|
FI3122757T3
(fi)
|
2014-02-28 |
2023-10-10 |
Hangzhou Dac Biotech Co Ltd |
Varautuneita linkkereitä ja niiden konjugointikäyttötapoja
|
|
CN106659800A
(zh)
|
2014-03-12 |
2017-05-10 |
诺华股份有限公司 |
用于修饰抗体以制备免疫缀合物的特定位点
|
|
PL3116999T3
(pl)
|
2014-03-14 |
2021-12-27 |
F.Hoffmann-La Roche Ag |
Sposoby i kompozycje do wydzielania polipeptydów heterologicznych
|
|
EP3119490B1
(de)
|
2014-03-21 |
2021-09-08 |
F. Hoffmann-La Roche AG |
In-vitro-prognose von in-vivo-halbwertzeit von antikörpern
|
|
MX2016012285A
(es)
|
2014-03-24 |
2017-01-23 |
Genentech Inc |
Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
|
|
WO2015153514A1
(en)
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
|
MA40682B1
(fr)
|
2014-03-31 |
2020-01-31 |
Hoffmann La Roche |
Anticorps anti-ox40 et procédés d'utilisation correspondants
|
|
EP3145952A2
(de)
|
2014-05-22 |
2017-03-29 |
Genentech, Inc. |
Anti-gpc3-antikörper und immunkonjugate
|
|
MX2016015163A
(es)
|
2014-05-23 |
2017-03-03 |
Genentech Inc |
Biomarcadores mit y metodos para su uso.
|
|
EP3154589A1
(de)
|
2014-06-13 |
2017-04-19 |
Genentech, Inc. |
Verfahren zur behandlung und prävention der antikrebsmittelresistenz
|
|
CN106687476B
(zh)
|
2014-06-26 |
2020-11-13 |
豪夫迈·罗氏有限公司 |
抗brdu抗体及使用方法
|
|
BR112017000130A2
(pt)
|
2014-07-11 |
2018-01-09 |
Genentech Inc |
método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
PE20170903A1
(es)
|
2014-08-12 |
2017-07-12 |
Novartis Ag |
Conjugados de farmacos con anticuerpos anti-cdh6
|
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
|
ES3034398T3
(en)
|
2014-08-28 |
2025-08-18 |
Bioatla Inc |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
TW201625688A
(zh)
|
2014-09-12 |
2016-07-16 |
建南德克公司 |
經半胱胺酸改造之抗體及接合物
|
|
US10149913B2
(en)
|
2014-09-12 |
2018-12-11 |
Genentech, Inc. |
Anthracycline disulfide intermediates, antibody-drug conjugates and methods
|
|
CN113698488A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
|
MA40579A
(fr)
|
2014-09-12 |
2016-03-17 |
Genentech Inc |
Anticorps anti-cll-1 et immunoconjugués
|
|
MY186334A
(en)
|
2014-09-12 |
2021-07-12 |
Genentech Inc |
Anti-her2 antibodies and immunoconjugates
|
|
US9732148B2
(en)
|
2014-10-16 |
2017-08-15 |
Genentech, Inc. |
Anti-α-synuclein antibodies and methods of use
|
|
JP2017537891A
(ja)
|
2014-10-31 |
2017-12-21 |
ジェネンテック， インコーポレイテッド |
抗ｉｌ−１７ａ及びｉｌ−１７ｆ交差反応性抗体変異体、ならびにそれらを含む組成物、それらを作製する方法、及び使用する方法
|
|
KR20170086540A
(ko)
|
2014-11-03 |
2017-07-26 |
제넨테크, 인크. |
T 세포 면역 하위세트를 검출하기 위한 검정 및 그의 사용 방법
|
|
EP3215637B1
(de)
|
2014-11-03 |
2019-07-03 |
F. Hoffmann-La Roche AG |
Verfahren und biomarker zur vorhersage der effizienz der behandlung mit ox40 agonisten
|
|
EP3215528B1
(de)
|
2014-11-06 |
2019-08-07 |
F.Hoffmann-La Roche Ag |
Fc-region-varianten mit modifizierte fcrn-bindung und verfahren zur verwendung
|
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
|
AU2015346460A1
(en)
|
2014-11-10 |
2017-03-23 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
PE20170912A1
(es)
|
2014-11-14 |
2017-07-12 |
Novartis Ag |
Conjugados de anticuerpo-farmaco
|
|
CN107108745B
(zh)
|
2014-11-19 |
2021-01-12 |
基因泰克公司 |
抗bace1的抗体和其用于神经疾病免疫疗法的用途
|
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
|
WO2016081640A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
CN107001482B
(zh)
|
2014-12-03 |
2021-06-15 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
|
AR102918A1
(es)
|
2014-12-05 |
2017-04-05 |
Genentech Inc |
Anticuerpos anti-cd79b y métodos de uso
|
|
CA2966365A1
(en)
|
2014-12-10 |
2016-06-16 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
|
SG10201710322VA
(en)
|
2014-12-19 |
2018-02-27 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
|
NZ730607A
(en)
|
2014-12-19 |
2022-07-01 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
|
AR103442A1
(es)
|
2015-01-16 |
2017-05-10 |
Juno Therapeutics Inc |
Anticuerpos y receptores de antígenos quiméricos específicos de ror1
|
|
CN107428823B
(zh)
|
2015-01-22 |
2021-10-26 |
中外制药株式会社 |
两种以上抗-c5抗体的组合与使用方法
|
|
WO2016125495A1
(en)
|
2015-02-05 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
|
CN115932273A
(zh)
|
2015-04-24 |
2023-04-07 |
豪夫迈·罗氏有限公司 |
鉴定包含结合多肽的细菌的方法
|
|
HK1250997A1
(zh)
|
2015-05-01 |
2019-01-18 |
基因泰克公司 |
掩蔽抗cd3抗体和使用方法
|
|
CN107592812A
(zh)
|
2015-05-11 |
2018-01-16 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
|
IL255312B
(en)
|
2015-05-12 |
2022-08-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
|
|
WO2016196343A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Humanized anti-ebola virus glycoprotein antibodies and methods of use
|
|
HK1248773A1
(zh)
|
2015-05-29 |
2018-10-19 |
豪夫迈‧罗氏有限公司 |
用於癌症的治疗和诊断方法
|
|
KR20180011839A
(ko)
|
2015-06-08 |
2018-02-02 |
제넨테크, 인크. |
항-ox40 항체를 이용한 암의 치료 방법
|
|
HK1251474A1
(zh)
|
2015-06-08 |
2019-02-01 |
豪夫迈‧罗氏有限公司 |
使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法
|
|
WO2016204966A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
CN107847568B
(zh)
|
2015-06-16 |
2022-12-20 |
豪夫迈·罗氏有限公司 |
抗cll-1抗体和使用方法
|
|
HRP20231134T1
(hr)
|
2015-06-16 |
2024-01-05 |
F. Hoffmann - La Roche Ag |
Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu
|
|
WO2016203432A1
(en)
|
2015-06-17 |
2016-12-22 |
Novartis Ag |
Antibody drug conjugates
|
|
HUE073235T2
(hu)
|
2015-06-17 |
2026-01-28 |
Hoffmann La Roche |
Anti-HER2 antitestek és alkalmazási eljárások
|
|
CR20210429A
(es)
|
2015-06-24 |
2021-09-24 |
Hoffmann La Roche |
ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562)
|
|
JP7021955B2
(ja)
|
2015-06-24 |
2022-03-03 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｈｅｒ２及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法
|
|
EP3313885A1
(de)
|
2015-06-29 |
2018-05-02 |
H. Hoffnabb-La Roche Ag |
Typ-ii-cd20-antikörper zur verwendung in der organtransplantation
|
|
EP3319936B1
(de)
|
2015-07-12 |
2025-12-17 |
Hangzhou Dac Biotech Co., Ltd. |
Brückenlinker zur konjugation von zellbindenden molekülen
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
EA201890434A1
(ru)
|
2015-08-05 |
2018-10-31 |
Янссен Байотек, Инк. |
Антитела к cd154 и способы их применения
|
|
EP3331569A1
(de)
|
2015-08-07 |
2018-06-13 |
Gamamabs Pharma |
Antikörper, antikörper-wirkstoff-konjugate und verfahren zur verwendung
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
JP6959912B2
(ja)
|
2015-09-23 |
2021-11-05 |
ジェネンテック， インコーポレイテッド |
抗ｖｅｇｆ抗体の最適化変異体
|
|
PH12018500645B1
(en)
|
2015-09-24 |
2022-10-21 |
Abvitro Llc |
Hiv antibody compositions and methods of use
|
|
PH12022553648A1
(en)
|
2015-09-25 |
2024-03-11 |
Genentech Inc |
Anti-tigit antibodies and methods of use
|
|
BR112018006360A2
(pt)
|
2015-09-30 |
2018-10-09 |
Janssen Biotech Inc |
anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
|
|
AU2016329251B2
(en)
|
2015-10-02 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Anti-PD1 antibodies and methods of use
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
TWI819458B
(zh)
|
2015-10-02 |
2023-10-21 |
瑞士商赫孚孟拉羅股份公司 |
雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
|
|
DK3356411T3
(da)
|
2015-10-02 |
2021-09-06 |
Hoffmann La Roche |
Bispecifikke antistoffer, der er specifikke for PD1 og TIM3
|
|
WO2017064675A1
(en)
|
2015-10-16 |
2017-04-20 |
Genentech, Inc. |
Hindered disulfide drug conjugates
|
|
EP3184547A1
(de)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg-antikörper und verfahren zur verwendung
|
|
ES2904553T3
(es)
|
2015-10-30 |
2022-04-05 |
Hoffmann La Roche |
Fragmentos de anticuerpo modificados con bisagra y procedimientos de preparación
|
|
KR20250099459A
(ko)
|
2015-11-03 |
2025-07-01 |
얀센 바이오테크 인코포레이티드 |
Pd-1과 특이적으로 결합하는 항체 및 그의 용도
|
|
CN108602884B
(zh)
|
2015-11-08 |
2024-06-25 |
豪夫迈·罗氏有限公司 |
筛选多特异性抗体的方法
|
|
EP3178848A1
(de)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
|
|
AU2016368469B2
(en)
|
2015-12-09 |
2023-11-02 |
F. Hoffmann-La Roche Ag |
Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
|
|
WO2017100402A1
(en)
*
|
2015-12-11 |
2017-06-15 |
Archer Daniels Midland Company |
One-pot synthesis of anhydropentitol esters from pentitols, catalyzed by water-tolerant lewis acids
|
|
PL3390442T3
(pl)
|
2015-12-18 |
2024-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Przeciwciała anty-c5 i sposoby ich stosowania
|
|
EP3390443A4
(de)
|
2015-12-18 |
2019-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin-antikörper, polypeptide mit abweichenden fc-regionen und verfahren zur verwendung
|
|
CN109196121B
(zh)
|
2016-02-29 |
2022-01-04 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
|
KR102775461B1
(ko)
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
EP3443004A1
(de)
|
2016-04-14 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Anti-rspo3-antikörper und verfahren zur verwendung
|
|
AU2017248644B2
(en)
|
2016-04-15 |
2019-10-31 |
Bioatla, Llc |
Anti-Axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
|
JP2019515670A
(ja)
|
2016-04-15 |
2019-06-13 |
ジェネンテック， インコーポレイテッド |
がんをモニタリングし治療するための方法
|
|
MX384141B
(es)
|
2016-04-15 |
2025-03-14 |
Genentech Inc |
Métodos para monitorear y terapias para usarse en tratar el cáncer.
|
|
SG11201809620UA
(en)
|
2016-05-02 |
2018-11-29 |
Hoffmann La Roche |
The contorsbody - a single chain target binder
|
|
TW201808336A
(zh)
|
2016-05-11 |
2018-03-16 |
賽諾菲公司 |
用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案
|
|
CN109071640B
(zh)
|
2016-05-11 |
2022-10-18 |
豪夫迈·罗氏有限公司 |
经修饰抗生腱蛋白抗体及使用方法
|
|
TWI851939B
(zh)
|
2016-05-13 |
2024-08-11 |
美商拜奧亞特拉公司 |
抗-ror2抗體、抗體片段、其免疫結合物及其用途
|
|
JP7022080B2
(ja)
|
2016-05-27 |
2022-02-17 |
ジェネンテック， インコーポレイテッド |
部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
|
|
CN110603266A
(zh)
|
2016-06-02 |
2019-12-20 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
|
|
EP3252078A1
(de)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
|
|
MX2018014375A
(es)
|
2016-06-17 |
2019-04-22 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina y metodos de uso.
|
|
US20190240346A1
(en)
*
|
2016-06-20 |
2019-08-08 |
Genahead Bio, Inc. |
Antibody-drug conjugate
|
|
WO2018023100A2
(en)
|
2016-07-29 |
2018-02-01 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies and related methods
|
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
|
BR112019001902A2
(pt)
|
2016-08-05 |
2019-07-09 |
Chugai Seiyaku Kabushiki Kaisha |
composição para profilaxia ou tratamento de doenças relacionadas à il-8
|
|
KR102512934B1
(ko)
|
2016-08-10 |
2023-03-23 |
레전드 바이오테크 아일랜드 리미티드 |
Bcma를 표적으로 하는 키메라 항원 수용체 및 이들의 이용 방법
|
|
JP7138094B2
(ja)
|
2016-08-25 |
2022-09-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
CN109689682B
(zh)
|
2016-09-19 |
2022-11-29 |
豪夫迈·罗氏有限公司 |
基于补体因子的亲和层析
|
|
EP3523451A1
(de)
|
2016-10-06 |
2019-08-14 |
Genentech, Inc. |
Therapeutische und diagnostische verfahren für krebs
|
|
US11555076B2
(en)
|
2016-10-29 |
2023-01-17 |
Genentech, Inc. |
Anti-MIC antibodies and methods of use
|
|
AU2016429272A1
(en)
|
2016-11-14 |
2019-05-02 |
Hangzhou Dac Biotech Co., Ltd. |
Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
|
|
KR20190074300A
(ko)
|
2016-11-15 |
2019-06-27 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
CA3036983A1
(en)
|
2016-11-21 |
2018-05-24 |
Cureab Gmbh |
Anti-gp73 antibodies and immunoconjugates
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
JP7304287B2
(ja)
|
2016-12-22 |
2023-07-06 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
|
|
CN110381980A
(zh)
|
2017-01-06 |
2019-10-25 |
艾维迪提生物科学有限责任公司 |
核酸-多肽组合物以及诱导外显子跳读的方法
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
BR112019016595A2
(pt)
|
2017-02-10 |
2020-03-31 |
Genentech, Inc. |
Anticorpos isolados, métodos de produção do anticorpo e de tratamento de um distúrbio, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, composições farmacêuticas e uso
|
|
CA3052670A1
(en)
|
2017-03-01 |
2018-09-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
SG11201909395TA
(en)
|
2017-04-27 |
2019-11-28 |
Tesaro Inc |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
US10772971B2
(en)
|
2017-06-22 |
2020-09-15 |
Mersana Therpeutics, Inc. |
Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
WO2019016772A2
(en)
|
2017-07-21 |
2019-01-24 |
Novartis Ag |
COMPOSITIONS AND METHODS FOR TREATING CANCER
|
|
EP3655034A1
(de)
|
2017-07-21 |
2020-05-27 |
Genentech, Inc. |
Therapeutische und diagnostische verfahren für krebs
|
|
US12235261B2
(en)
|
2017-10-20 |
2025-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Method for measuring cellular uptake of molecules
|
|
AU2018358883B2
(en)
|
2017-10-30 |
2025-09-25 |
F. Hoffmann-La Roche Ag |
Method for in vivo generation of multispecific antibodies from monospecific antibodies
|
|
EP3704150A1
(de)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Compbody ein multivalentes zielbindemittel
|
|
CA3080904A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
|
PL3704146T3
(pl)
|
2017-11-01 |
2022-03-07 |
F. Hoffmann-La Roche Ag |
Przeciwciało Contorsbody trifab
|
|
CN111213059B
(zh)
|
2017-11-06 |
2024-01-09 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
|
EP3710589A4
(de)
|
2017-11-14 |
2021-11-10 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c1s-antikörper und verfahren zur verwendung
|
|
CN118638788A
(zh)
|
2017-12-06 |
2024-09-13 |
艾维迪提生物科学公司 |
治疗肌萎缩和强直性肌营养不良的组合物和方法
|
|
EP3732195A4
(de)
|
2017-12-28 |
2022-02-09 |
Chugai Seiyaku Kabushiki Kaisha |
Zytotoxizitätsinduzierendes therapeutikum
|
|
WO2019139987A1
(en)
|
2018-01-09 |
2019-07-18 |
Elstar Therapeutics, Inc. |
Calreticulin binding constructs and engineered t cells for the treatment of diseases
|
|
WO2019143636A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
WO2019154776A1
(en)
|
2018-02-06 |
2019-08-15 |
F. Hoffmann-La Roche Ag |
Treatment of ophthalmologic diseases
|
|
AR115360A1
(es)
|
2018-02-08 |
2021-01-13 |
Genentech Inc |
Moléculas de unión al antígeno y métodos de uso
|
|
MX2020008882A
(es)
|
2018-02-26 |
2021-01-08 |
Genentech Inc |
Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
|
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
CA3093729A1
(en)
|
2018-03-15 |
2019-09-19 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
|
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
WO2019222294A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
US20210130430A1
(en)
|
2018-05-14 |
2021-05-06 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
CN113840832A
(zh)
|
2018-05-14 |
2021-12-24 |
狼人治疗公司 |
可活化白介素-2多肽及其使用方法
|
|
MA52777A
(fr)
|
2018-05-24 |
2021-04-14 |
Janssen Biotech Inc |
Agents de liaison psma et utilisations correspondantes
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
IL317002A
(en)
|
2018-08-10 |
2025-01-01 |
Chugai Pharmaceutical Co Ltd |
Anti-CD137 antigen binding molecule and use thereof
|
|
WO2020052542A1
(en)
|
2018-09-10 |
2020-03-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against cll1 and constructs thereof
|
|
KR20210063330A
(ko)
|
2018-09-19 |
2021-06-01 |
제넨테크, 인크. |
방광암에 대한 치료 및 진단 방법
|
|
MX2021003543A
(es)
|
2018-09-27 |
2021-06-23 |
Xilio Dev Inc |
Polipeptidos de citocinas enmascaradas.
|
|
AU2019361983A1
(en)
|
2018-10-18 |
2021-05-20 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
SG11202103064YA
(en)
|
2018-10-29 |
2021-05-28 |
Hoffmann La Roche |
Antibody formulation
|
|
MX2021004906A
(es)
|
2018-10-29 |
2021-09-10 |
Mersana Therapeutics Inc |
Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos.
|
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
CN113227131B
(zh)
|
2018-12-20 |
2025-03-04 |
豪夫迈·罗氏有限公司 |
经修饰的抗体Fc及其使用方法
|
|
PH12021551479A1
(en)
|
2018-12-21 |
2022-07-18 |
Novartis Ag |
Antibodies to pmel17 and conjugates thereof
|
|
IL319265A
(en)
|
2018-12-21 |
2025-04-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and their uses
|
|
EP3902833A2
(de)
|
2018-12-26 |
2021-11-03 |
City of Hope |
Aktivierbare maskierte anti-ctla4-bindende proteine
|
|
BR112021014276A2
(pt)
|
2019-01-22 |
2021-09-28 |
Genentech, Inc. |
Anticorpos iga isolados, moléculas de fusão igg-iga isoladas, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, para tratar um indivíduo, para aumentar a expressão de dímeros, trímeros ou tetrâmeros, para aumentar a produção de polímeros, para aumentar a produção de dímeros, para aumentar a produção de um polímero, para diminuir a produção de polímeros, para aumentar a expressão transitória de um anticorpo, para expressar dímeros de moléculas de fusão, para expressar dímeros, trímeros ou tetrâmeros, para purificar um anticorpo, para purificar um estado oligomérico de um anticorpo, composição farmacêutica e uso do anticorpo
|
|
EP3915581A4
(de)
|
2019-01-24 |
2023-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Neuartige krebsantigene und antikörper dieser antigene
|
|
CA3123303A1
(en)
|
2019-01-29 |
2020-08-06 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
|
GB2597851B
(en)
|
2019-02-21 |
2024-05-29 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKP30 and uses thereof
|
|
AU2020226893B2
(en)
|
2019-02-21 |
2025-02-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
BR112021016923A2
(pt)
|
2019-02-27 |
2021-11-03 |
Genentech Inc |
Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
|
|
MA55296A
(fr)
|
2019-03-14 |
2022-03-23 |
Hoffmann La Roche |
Traitement du cancer avec des anticorps bispécifiques de her2xcd3 en combinaison avec un mab anti-her2
|
|
WO2020187998A1
(en)
|
2019-03-19 |
2020-09-24 |
Fundació Privada Institut D'investigació Oncològica De Vall Hebron |
Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
|
|
MX2021012692A
(es)
|
2019-04-19 |
2021-11-12 |
Genentech Inc |
Anticuerpos anti-mertk y sus metodos de uso.
|
|
AR118720A1
(es)
|
2019-04-19 |
2021-10-27 |
Janssen Biotech Inc |
Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
|
|
CA3137715A1
(en)
|
2019-04-25 |
2020-10-29 |
Avidity Biosciences, Inc. |
Nucleic acid compositions and methods of multi-exon skipping
|
|
KR20220023988A
(ko)
|
2019-05-14 |
2022-03-03 |
웨어울프 세라퓨틱스, 인크. |
분리 모이어티 및 이의 사용 방법
|
|
CN114096562B
(zh)
|
2019-05-15 |
2025-02-21 |
中外制药株式会社 |
抗原结合分子、药物组合物和方法
|
|
PH12021552960A1
(en)
|
2019-07-10 |
2022-07-25 |
Chugai Pharmaceutical Co Ltd |
Claudin-6 binding molecules and uses thereof
|
|
JP2022548978A
(ja)
|
2019-09-27 |
2022-11-22 |
ジェネンテック， インコーポレイテッド |
薬抗ｔｉｇｉｔ及び抗ｐｄ－ｌ１アンタゴニスト抗体を用いた処置のための投薬
|
|
WO2021092171A1
(en)
|
2019-11-06 |
2021-05-14 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
|
BR112022009110A2
(pt)
|
2019-11-14 |
2022-07-26 |
Werewolf Therapeutics Inc |
Polipeptídeos de citocina ativáveis e métodos de uso destes
|
|
KR20220122653A
(ko)
|
2019-12-06 |
2022-09-02 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｂｃｍａ-표적 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법
|
|
CN115335399A
(zh)
|
2019-12-06 |
2022-11-11 |
朱诺治疗学股份有限公司 |
针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法
|
|
BR112022011357A2
(pt)
|
2019-12-13 |
2022-08-23 |
Genentech Inc |
Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
|
|
KR102645629B1
(ko)
|
2019-12-27 |
2024-03-07 |
추가이 세이야쿠 가부시키가이샤 |
항ctla-4 항체 및 그의 사용
|
|
AU2020416273A1
(en)
|
2020-01-03 |
2022-07-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
JP7846624B2
(ja)
|
2020-01-09 |
2026-04-15 |
メルサナ セラピューティクス インコーポレイテッド |
ペプチド含有リンカーとの部位特異的抗体－薬物コンジュゲート
|
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
TWI895351B
(zh)
|
2020-02-12 |
2025-09-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
|
JP7767298B2
(ja)
|
2020-03-13 |
2025-11-11 |
ジェネンテック， インコーポレイテッド |
抗インターロイキン－３３抗体及びその使用
|
|
WO2021188390A1
(en)
|
2020-03-19 |
2021-09-23 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
|
CR20220524A
(es)
|
2020-03-19 |
2022-12-02 |
Genentech Inc |
Anticuerpos anti-tgf-beta con selectividad de isoforma y métodos de uso
|
|
WO2021195469A1
(en)
|
2020-03-27 |
2021-09-30 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle dystrophy
|
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
|
CN115885050A
(zh)
|
2020-04-28 |
2023-03-31 |
基因泰克公司 |
用于非小细胞肺癌免疫疗法的方法和组合物
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
WO2021252977A1
(en)
|
2020-06-12 |
2021-12-16 |
Genentech, Inc. |
Methods and compositions for cancer immunotherapy
|
|
CN115916348A
(zh)
|
2020-06-18 |
2023-04-04 |
基因泰克公司 |
使用抗tigit抗体和pd-1轴结合拮抗剂的治疗
|
|
US20230256114A1
(en)
|
2020-07-07 |
2023-08-17 |
Bionecure Therapeutics, Inc. |
Novel maytansinoids as adc payloads and their use for the treatment of cancer
|
|
TW202204895A
(zh)
|
2020-07-13 |
2022-02-01 |
美商建南德克公司 |
預測多肽免疫性的基於細胞之方法
|
|
WO2022012680A1
(en)
|
2020-07-16 |
2022-01-20 |
Nanjing Legend Biotech Co., Ltd. |
Cd20 binding molecules and uses thereof
|
|
CN115917313A
(zh)
|
2020-07-29 |
2023-04-04 |
中外制药株式会社 |
非放射性物质标记的药剂的药代动力学的测定方法
|
|
JP2023536326A
(ja)
|
2020-08-05 |
2023-08-24 |
ジュノー セラピューティクス インコーポレイテッド |
Ｒｏｒ１標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
|
|
CN115836122A
(zh)
|
2020-08-07 |
2023-03-21 |
基因泰克公司 |
用于预测多肽免疫原性的基于t细胞的方法
|
|
PE20230983A1
(es)
|
2020-08-07 |
2023-06-21 |
Genentech Inc |
Proteinas de fusion del ligando para flt3 y metodos de uso
|
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
TWI874719B
(zh)
|
2020-11-04 |
2025-03-01 |
美商建南德克公司 |
用抗cd20/抗cd3雙特異性抗體進行治療之給藥
|
|
KR20230095113A
(ko)
|
2020-11-04 |
2023-06-28 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이적 항체들과 항-cd79b 항체 약물 접합체들을 이용한 치료를 위한 투약
|
|
AU2021374590A1
(en)
|
2020-11-04 |
2023-06-01 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
|
EP4000635A1
(de)
*
|
2020-11-16 |
2022-05-25 |
Frank J. Hernandez |
Nukleasenaktivierte therapeutische oligonukleotide
|
|
CR20230283A
(es)
|
2020-11-24 |
2023-07-27 |
Novartis Ag |
Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos
|
|
JP2023553323A
(ja)
|
2020-11-25 |
2023-12-21 |
エクシリオ デベロップメント， インコーポレイテッド |
腫瘍特異的に切断可能なリンカー
|
|
WO2022116877A1
(en)
|
2020-12-02 |
2022-06-09 |
Shanghai Henlius Biotech, Inc. |
ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
|
|
CR20230263A
(es)
|
2020-12-17 |
2023-08-21 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de estos
|
|
KR20230137393A
(ko)
|
2021-01-28 |
2023-10-04 |
얀센 바이오테크 인코포레이티드 |
Psma 결합 단백질 및 이의 용도
|
|
WO2022187270A1
(en)
|
2021-03-01 |
2022-09-09 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
|
EP4301781A1
(de)
|
2021-03-01 |
2024-01-10 |
Xilio Development, Inc. |
Kombination von maskierten ctla4 und pd1/pdl1-antikörpern zur behandlung von krebs
|
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
|
WO2022221720A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
AU2021443863A1
(en)
|
2021-04-30 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
WO2022228705A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
EP4342984A4
(de)
|
2021-05-19 |
2025-04-23 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur vorhersage der in-vivo-pharmazekinetik eines moleküls
|
|
WO2022255440A1
(en)
|
2021-06-04 |
2022-12-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
|
TW202527987A
(zh)
|
2021-06-25 |
2025-07-16 |
日商中外製藥股份有限公司 |
抗ctla-4抗體的用途
|
|
AR126220A1
(es)
|
2021-06-25 |
2023-09-27 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-ctla-4
|
|
KR20240049342A
(ko)
|
2021-08-27 |
2024-04-16 |
얀센 바이오테크 인코포레이티드 |
항-psma 항체 및 이의 용도
|
|
MX2024003266A
(es)
|
2021-09-16 |
2024-04-03 |
Avidity Biosciences Inc |
Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
|
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
|
MX2024004117A
(es)
|
2021-10-08 |
2024-04-19 |
Chugai Pharmaceutical Co Ltd |
Metodo para preparar formulacion de jeringa precargada.
|
|
CN117980327A
(zh)
|
2021-11-03 |
2024-05-03 |
杭州多禧生物科技有限公司 |
抗体的特异性偶联
|
|
EP4433506A1
(de)
|
2021-11-16 |
2024-09-25 |
Genentech, Inc. |
Verfahren und zusammensetzungen zur behandlung von systemischem lupus erythematodes (sle) mit momonetuzumab
|
|
AU2022408865A1
(en)
|
2021-12-17 |
2024-07-04 |
Shanghai Henlius Biologics Co., Ltd. |
Anti-ox40 antibodies, multispecific antibodies and methods of use
|
|
JP2025501522A
(ja)
|
2021-12-17 |
2025-01-22 |
シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド |
抗ｏｘ４０抗体及び使用方法
|
|
UY40097A
(es)
|
2022-01-07 |
2023-07-14 |
Johnson & Johnson Entpr Innovation Inc |
Materiales y métodos de proteínas de unión a il-1b
|
|
WO2023157989A1
(ko)
|
2022-02-17 |
2023-08-24 |
주식회사 노벨티노빌리티 |
항체-약물 접합체
|
|
WO2023180353A1
(en)
|
2022-03-23 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
|
CN118974096A
(zh)
|
2022-03-25 |
2024-11-15 |
上海复宏汉霖生物技术股份有限公司 |
抗msln抗体及使用方法
|
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
CN119384432A
(zh)
|
2022-04-13 |
2025-01-28 |
基因泰克公司 |
治疗性蛋白质的药物组合物和使用方法
|
|
CA3255366A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use
|
|
WO2023215293A1
(en)
|
2022-05-02 |
2023-11-09 |
Athanor Biosciences, Inc. |
Cancer eradicating – bio-nanoparticles (ce-bnp)
|
|
CN119317641A
(zh)
|
2022-05-11 |
2025-01-14 |
基因泰克公司 |
针对用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
|
|
IL317449A
(en)
|
2022-06-07 |
2025-02-01 |
Genentech Inc |
Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
|
|
KR20250039386A
(ko)
|
2022-07-13 |
2025-03-20 |
제넨테크, 인크. |
항-fcrh5/항-cd3 이중특이적 항체를 이용한 치료를 위한 투약법
|
|
CN119836306A
(zh)
|
2022-07-15 |
2025-04-15 |
费恩治疗有限公司 |
与cdcp1结合的抗体药物缀合物和其用途
|
|
TW202413433A
(zh)
|
2022-07-19 |
2024-04-01 |
美商建南德克公司 |
用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
|
|
KR20250041021A
(ko)
|
2022-07-22 |
2025-03-25 |
제넨테크, 인크. |
항-steap1 항원 결합 분자 및 이의 용도
|
|
CN120153254A
(zh)
|
2022-09-01 |
2025-06-13 |
基因泰克公司 |
膀胱癌的治疗和诊断方法
|
|
TW202426505A
(zh)
|
2022-10-25 |
2024-07-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
|
AU2023370106A1
(en)
|
2022-10-25 |
2025-05-08 |
Fundació Privada Institut D'investigació Oncològica De Vall Hebron |
Combination therapy for the treatment of cancer
|
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|
|
WO2024129778A2
(en)
|
2022-12-13 |
2024-06-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
|
AU2024270495A1
(en)
|
2023-05-05 |
2025-10-09 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024251846A1
(en)
|
2023-06-07 |
2024-12-12 |
Fundació Privada Institut D'investigació Oncològica De Vall Hebron |
Combination therapy with mek inhibitors for the treatment of cancer
|
|
KR20260020418A
(ko)
|
2023-06-07 |
2026-02-11 |
펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론 |
Braf 저해제를 이용한 암 치료용 조합 요법
|
|
EP4473974A1
(de)
|
2023-06-07 |
2024-12-11 |
Peptomyc, S.L. |
Omomyc und kras-hemmern kombinationstherapie zur behandlung von krebs
|
|
WO2025106474A1
(en)
|
2023-11-14 |
2025-05-22 |
Genentech, Inc. |
Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2026030464A1
(en)
|
2024-07-30 |
2026-02-05 |
Genentech, Inc. |
Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy
|